Eli Lilly’s tirzepatide cuts risk of worsening heart failure in HFpEF, obese patients
Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...
NIAID Exercises Option to Continue Preclinical Development of Bolder BioTechnology's BBT-059 IL-11 Analog to Treat Acute Radiation Syndrome
Bolder BioTechnology, Inc. announced today that the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option to fund the second year of ...
News Medical on MSN4h
Tirzepatide improves heart health and function in obese HFpEF patients
In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...